Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.21.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 14,660 $ 7,152
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 14,660 7,152
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,239 2,045
Collaboration and License Agreements and Supply Agreements | Merck    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 11,883 2,777
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 220 2,294
Collaboration and License Agreements and Supply Agreements | Vaxcyte    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 1,318 $ 36